This hypothesis was tested in which a siRNA against CD44 was combined with paclitaxel and loaded in a dendrimer functionalized with the luteinizing hormone-releasing hormone (LHRH) peptide to confer the nanosystem targeting properties to cancer cells of gynecologic origin (228). Here, CD44 is linked to cancer.